Matches in Nanopublications for { ?s ?p "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP800416.RA6OXXDgfSHLUzneIew-XqFShnakX6h6NzD5unNHaIS5M130_assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP800416.RA6OXXDgfSHLUzneIew-XqFShnakX6h6NzD5unNHaIS5M130_provenance.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.